


**Product Name** : Caficrestat  
**Cat. No.** : PC-45580  
**CAS No.** : 1355612-71-3  
**Molecular Formula** : C<sub>17</sub>H<sub>10</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>S  
**Molecular Weight** : 421.3532  
**Target** : Aldose Reductase  
**Solubility** : DMSO: ≥ 28 mg/mL  
 1. Juan Gaztanaga, et al. Diabetes Metab Syndr. Nov-Dec 2021;15(6):102328.



## Biological Activity

AT-001 (Caficrestat) is a highly potent, selective inhibitor of **aldose reductase** enzymatic activity with IC<sub>50</sub> of 28.9 pM. AT-001 (Caficrestat) decreases biomarkers of myocardial stress and is currently being studied in a Phase 3 global registrational study in patients with diabetic cardiomyopathy (ARISE-HF). AT-001 (Caficrestat) reduces viral inflammation and risk of adverse outcomes in diabetic patients with COVID-19.

## References

